Blood Pressure Medications with Gastrointestinal Effects in Ulcerative Colitis
In patients with ulcerative colitis on upadacitinib and prednisone, calcium channel blockers (specifically amlodipine) or thiazide diuretics are the preferred first-line antihypertensive agents, as they lack significant drug interactions with JAK inhibitors and do not exacerbate gastrointestinal symptoms. 1
Preferred Antihypertensive Agents
First-Line Recommendations
Amlodipine 5-10 mg daily is recommended as the optimal calcium channel blocker, offering once-daily dosing with no significant drug interactions with upadacitinib or prednisone 1
Hydrochlorothiazide 12.5-25 mg daily can be used as an alternative thiazide diuretic, though close monitoring for electrolyte disturbances is essential given the risk of hypokalemia in active colitis 1
Critical Monitoring Requirements
Weekly home blood pressure monitoring is mandatory for the first month after starting upadacitinib in patients with preexisting hypertension 1
Blood pressure should be assessed every 3 months for the first 3 months of upadacitinib therapy, then every 6 months thereafter during maintenance therapy 1
Serum potassium monitoring is essential if using thiazide diuretics, as both the diuretic and active colitis increase hypokalemia risk 1
Antihypertensive Agents to Avoid
ACE Inhibitors and ARBs
While ACE inhibitors and ARBs are recommended as first-line agents for hypertension in diabetic patients generally 2, their use requires careful consideration in the context of acute ulcerative colitis:
These agents require renal function and serum potassium monitoring within the first 3 months, then every 6 months 2
In patients with active colitis who may have fluid and electrolyte disturbances, this monitoring becomes more complex 1
Beta-Blockers
Beta-blockers are listed as agents that reduce cardiovascular events in diabetic patients 2, but no specific guidance addresses their use in ulcerative colitis patients
They are not contraindicated but are not the preferred first-line choice given the availability of calcium channel blockers with better evidence in this population 1
Special Considerations for Acute Severe UC
Fluid Management
Intravenous fluid and electrolyte replacement to correct dehydration may improve blood pressure control and should be prioritized before escalating antihypertensive therapy 1
Thromboprophylaxis with subcutaneous low-molecular-weight heparin is mandatory in all hospitalized acute severe UC patients unless contraindicated 1
Multidisciplinary Management
- Joint gastroenterologist and colorectal surgeon management is required for acute severe UC, ensuring coordinated decision-making about both the colitis and its complications, including hypertension management 1
Drug Interaction Considerations
Upadacitinib-Specific Concerns
Upadacitinib has been associated with hypertension as an adverse effect, requiring proactive blood pressure monitoring 3
The FDA label for upadacitinib notes various adverse events but does not specifically contraindicate any particular antihypertensive class 4
No gastrointestinal perforations were reported in placebo-controlled trials with upadacitinib 15 mg, though 2 cases occurred with the 30 mg dose in MTX-controlled trials 4
Corticosteroid Effects
Prednisone doses ≥20 mg daily are associated with increased risk of complications, including potential effects on blood pressure 5
Patients on high-dose steroids require enhanced monitoring for all complications, including cardiovascular effects 6
Common Pitfalls to Avoid
Do not use multiple-drug antihypertensive therapy without first optimizing fluid status in acute colitis patients, as dehydration may be contributing to blood pressure elevation 1
Avoid abrupt changes in antihypertensive regimens during acute UC flares, as hemodynamic instability may complicate disease management 1
Do not delay thromboprophylaxis while managing hypertension, as venous thromboembolism risk is elevated with both JAK inhibitors and active inflammatory bowel disease 5, 4